Wyoming Department of Health

Public Health Division
122 West 25th Street, 3rd Floor West
Cheyenne, WY 82002
(307) 777-6340 • 866-571-0944
Fax (307) 777-8264 • www.health.wyo.gov

Michael A. Ceballos
Director

Mark Gordon
Governor

May 12, 2020

Ref: AH-2020-017

Dear Wyoming Hospital Chief Executive Officers and Chief Medical Officers:

On May 12, 2020, the Wyoming Department of Health (WDH) received a shipment of Remdesivir from the Federal Emergency Management Agency (FEMA). Remdesivir is an intravenous antiviral drug that has received an Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA) for the treatment of suspected or laboratory-confirmed coronavirus disease 2019 (COVID-19) among adults and children hospitalized with severe disease. Severe disease is defined as patients with an oxygen saturation (SpO2) ≤ 94% on room air or requiring supplemental oxygen or requiring mechanical ventilation or requiring extracorporeal membrane oxygenation (ECMO).

The EUA for Remdesivir can be found here: FDA EUA Remdesivir. The FDA's Fact Sheet for Health Care Providers can be found here: FDA Remdesivir Health Care Provider Fact Sheet.

WDH will receive 200 Remdesivir injection 5mg/mL vials, each containing 100 mg of drug. This represents treatment for approximately 18-33 patients dependent on the dosing regimens required, which for adults can range from 600 mg to 1,100 mg based on severity of illness.

Because of the limited supply of Remdesivir that Wyoming will receive, and to ensure that Remdesivir is available to severely ill patients with COVID-19 throughout Wyoming, WDH will supply Remdesivir to hospitals on request to treat specific patients who meet the FDA criteria for its use. Providers caring for hospitalized patients who meet the FDA criteria for treatment with Remdesivir can request a course of the medication by calling WDH's 24/7 Public Health Emergency Line at 1-888-996-9104. The provider will be asked a series of questions (see list below) to ensure the patient meets criteria for treatment with Remdesivir. WDH will then supply the hospital with the requested course. The WDH will make every effort to deliver the requested course within 12 hours of the request.

It is not known at this time whether WDH will receive additional shipments of Remdesivir. In order to ensure that Remdesivir is available to severely ill patients, WDH asks

that providers request the medication for patients who have laboratory-confirmed COVID-19, who are worsening despite supportive measures or are unlikely to improve with supportive measures alone, and who are likely to require hospitalization for at least 5 days, the length of the shortest possible course of treatment.

Providers treating COVID-19 patients with Remdesivir must report all medication errors and all serious adverse events to the FDA according to the instructions found on FDA's Fact Sheet for Health Care Providers. Providers must also be familiar with the contraindications to administering Remdesivir and the required monitoring for patients being treated with Remdesivir found in the Fact Sheet. For patients that receive Remdesivir, providers must document in the medical record that the patient or caregiver has been given the Fact Sheet for Patients and Parents/Caregivers (Fact Sheet for Patients and Parent/Caregivers: Emergency Use Authorization (EUA) of Remdesiver for COVID-19), informed of alternatives to receiving Remdesivir, and informed that Remdesivir is an unapproved drug that is authorized for use under an EUA.

This letter will also be sent to licensed Wyoming health care providers through the Wyoming Alert and Response Network.

Thank you for all of your efforts during the COVID-19 pandemic response.

Sincerely,

Alexia Harrist, MD, Ph.D
State Health Officer
Public Health Division

AH/ah

c: Michael A. Ceballos, Director, Department of Health
Stephanie Pyle, MBA, Senior Administrator, Public Health Division

Remdesivir Request Required Information

1. Patient name
2. Patient date of birth
3. Hospital
4. Date hospitalized
5. Patient status
    a. Does the patient have laboratory-confirmed COVID-19?
    b. Does the patient have an oxygen saturation of ≤ 94% on room air?
    c. Does the patient require supplemental oxygen?
    d. Does the patient require mechanical ventilation?
    e. Is the patient receiving extracorporeal membrane oxygenation (ECMO)?
    f. Is the patient improving, stable, or worsening with supportive therapy?
    g. Is the patient in intensive care?
6. Do you anticipate that the patient will require hospitalization for at least 5 days?
7. Requested number of doses (6 or 11)
8. Requesting provider and provider phone number
9. Pharmacy contact for medication delivery